Acciona Infrastructure and Transport for NSW are currently in settlement talks over a $1.2 billion dispute around the NSW government’s ongoing light rail project in Sydney.
AMP contractor pleads guilty to stealing customer data
Wyeth defends validity of patents in trial over best-selling Prevnar 13 vaccine
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a “ceiling” of 11 types of pneumococcal bacteria that could be included in a single vaccine.